Anzeige
Mehr »
Mittwoch, 06.08.2025 - Börsentäglich über 12.000 News
US-Kupfer-Geheimtipp legt nach: Strategisches Projekt zündet Phase 2 mit KI-Bohrplanung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 896047 | ISIN: US09058V1035 | Ticker-Symbol: BO1
Tradegate
06.08.25 | 19:40
7,380 Euro
+2,07 % +0,150
1-Jahres-Chart
BIOCRYST PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
BIOCRYST PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
7,3207,37820:09
7,3207,37820:09

Aktuelle News zur BIOCRYST PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13:06BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)34RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted...
► Artikel lesen
MoBioCryst targets $1B ORLADEYO peak and $700M cash by 2027 as leadership shifts and pipeline advances5
BIOCRYST PHARMACEUTICALS Aktie jetzt für 0€ handeln
MoBioCryst Q2 2025 slides: ORLADEYO demand surges, profitability accelerates6
MoBioCryst: Hohe ORLADEYO-Nachfrage beschleunigt Profitabilität14
MoBioCryst: EPS übertrifft Schätzungen um 0,14 $ - Umsatz besser als erwartet6
MoBioCryst Pharmaceuticals Non-GAAP EPS of $0.15 beats by $0.12, revenue of $163.4M beats by $13.58M3
FrEarnings Outlook For BioCryst Pharma4
FrBioCryst Pharmaceuticals Q2 2025 Earnings Preview10
DoBioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock6
DoBioCryst appoints Charlie Gayer to succeed Jon Stonehouse as CEO1
DoBioCryst Pharmaceuticals announces leadership transition as CEO plans retirement4
DoBioCryst Pharmaceuticals, Inc.: BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December185RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief executive officer, Jon Stonehouse, has informed...
► Artikel lesen
DoBIOCRYST PHARMACEUTICALS INC - 8-K, Current Report1
24.07.RBC Capital: BioCryst-Aktie vor Quartalszahlen unterbewertet9
24.07.BioCryst stock undervalued ahead of Q2 earnings, says RBC Capital3
21.07.BioCryst Pharmaceuticals, Inc.: BioCryst to Report Second Quarter 2025 Financial Results on August 42
12.07.RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $1311
07.07.BioCryst Pharma Appoints Babar Ghias As CFO-
07.07.BioCryst appoints Babar Ghias as CFO1
07.07.BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development506RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head...
► Artikel lesen
Weiter >>
108 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1